Drug Updates & News
Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults.
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia.
Oncology nurses may believe that personal exposure to hazardous drugs is a thing of the past, but they would be wrong.
Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer
There is an urgent unmet need for more effective therapies in pancreatic cancer.
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner.
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 231,840 American women will be diagnosed with breast cancer, and nearly 40,300 women will die from the disease in 2015.
Peter Tang, PharmD Candidate, Tristan Lindfelt, PharmD, BCPS, BCACP, BCOP, Robert J. Ignoffo, PharmD, FASHP, FCSHP
It is estimated that in 2014 there will be 15,720 new cases of chronic lymphocytic leukemia (CLL) and 4600 deaths from CLL, making it the second most common leukemia in adults in the United States. The average age at diagnosis is approximately 72 years.
Page 1 of 4
Results 1 - 10 of 38
Results 1 - 10 of 38